about
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionAcquired immunity to malariaUnexpected fold in the circumsporozoite protein target of malaria vaccinesIdentification of a highly antigenic linear B cell epitope within Plasmodium vivax apical membrane antigen 1 (AMA-1)Protease inhibitors from marine actinobacteria as a potential source for antimalarial compoundSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenA multifunctional serine protease primes the malaria parasite for red blood cell invasionMeta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues.Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development.A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coliPopulation diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic settingThe Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infectionsIn vitro growth-inhibitory activity and malaria risk in a cohort study in maliAntiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarrayCloning, expression and transmission-blocking activity of anti-PvWARP, malaria vaccine candidate, in Anopheles stephensi mysorensis.Evaluation of three medicinal plant extracts against Plasmodium falciparum and selected microganisms.Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth.Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines.Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2.High-Level Expression of Immunogenic Recombinant Plasmodium vivax Merozoite Surface Protein (Pvmsp-142 kDa) in pGEX 6P1 Vector.A recombinant Plasmodium vivax apical membrane antigen-1 to detect human infection in IranPlasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria.Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communitiesStability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen 1 and thrombospondin-related adhesive protein immunodominant epitopes in a highland population from Western KenyaSickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria.Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis.Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimodSynthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.Malaria vaccines: a toy for travelers or a tool for eradication?Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.How might infant and paediatric immune responses influence malaria vaccine efficacy?Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum.Malaria vaccines: past, present and future.Isolation and expression of UB05, a Plasmodium falciparum antigen recognised by antibodies from semi-immune adults in a high transmission endemic area of the Cameroonian rainforest.Malaria vaccine efficacy: overcoming the helminth hurdle.
P2860
Q24628167-7A592DD0-C6BB-4012-AF0B-0023C66964A4Q24651173-41E4A732-CF3A-4410-B474-727D6207BFF0Q27678840-4C753FB6-1ED9-40AC-9D2B-5A586FDDEF63Q28478668-A9EE084A-E7C2-4223-B02B-38ED82102693Q28540732-833AFDD8-8440-4184-9DF5-FFE63EF72ABBQ28744573-3BF2474B-29A7-4AC3-83B8-C7A73C6C7D43Q30043444-AF5066A6-63CA-4BD9-B2C4-FE391BFCEAD0Q33400526-8E616DD6-B81E-4B13-BCA8-C45E324D678DQ33459259-FA84E133-816B-4DC8-9913-04A00AB97DB2Q33485233-66AF5666-B599-47B3-BE96-7443BD87507CQ33510819-9CA86A6F-149B-4D38-8A57-FE6FACA62B8CQ33587496-E8F14E95-D7F5-4739-9FD3-E1C571DFCD15Q33613892-520B7763-2C87-469C-AFD6-C763BDD7ED79Q33670827-0B1C9E3D-A604-40C7-8CAF-65455417FAEFQ33859633-C47C622C-D742-41A3-AEA3-1EECF6902957Q33998171-4BC874BE-9D9B-4240-B690-CD0D1ACED41EQ34367208-FF6E3D3B-6B05-46F1-B66F-2DB26192DB55Q34369560-77906CAE-2791-409F-A3C7-F2C8D0F9EE14Q35010158-6673215A-1A62-49A5-BB35-00E360F79542Q35607939-B57C283D-9DF7-4BBB-92BE-332F65039AABQ35668254-A70213CB-2374-4522-8AB4-BD3C984BE34CQ35842665-FFEA942F-A636-41F0-B5C5-EFB7236B89C5Q35944117-4D158B2F-4A40-4A91-A6F2-5DEB51B9D12DQ35961275-CA65EF9C-912C-4686-8CA5-9D598BCAFA2BQ36791117-F6934DA7-6E30-45A8-8D5A-CD9EA9DF974FQ36953171-0595947F-2FD6-4BBB-A8FB-1623A2F1FA3DQ36972498-6E17A024-FDC3-417A-8E01-356E5CC411E1Q37075435-231D314B-3BD9-4C8B-BBF3-0AA5C3835066Q37169192-98DA5F5E-7ED7-4C3F-9E3C-7DD6CE7FE4D2Q37194780-7BCA38E2-5897-4915-964D-020461DC48D2Q37256085-89D0366D-74EB-4249-88CF-D3406C7937A8Q37382587-163A7F09-25B6-4662-93B4-AF1F35549F06Q37867102-669E3A2F-8DC9-403E-B9F0-C5EB84F2381CQ39320768-46DF6E93-8E44-4CCE-838E-C701B51F11E9Q39345614-944A6F40-5790-4EFD-8996-F2723332D0FDQ43281332-1B54499F-AC1B-462B-A954-D2F7C95A574BQ44942699-EB7407E4-AC0E-42A1-8E6E-92EFEE5B2C2D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasmodium falciparum malaria vaccines in development.
@en
Plasmodium falciparum malaria vaccines in development.
@nl
type
label
Plasmodium falciparum malaria vaccines in development.
@en
Plasmodium falciparum malaria vaccines in development.
@nl
prefLabel
Plasmodium falciparum malaria vaccines in development.
@en
Plasmodium falciparum malaria vaccines in development.
@nl
P2860
P356
P1476
Plasmodium falciparum malaria vaccines in development.
@en
P2093
Johan Vekemans
P2860
P304
P356
10.1586/14760584.7.2.223
P577
2008-03-01T00:00:00Z